NCT07545811RecruitingPhase 1
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants With Prostate Cancer
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- First submitted
- 16 Apr 2026
- Start date
- 15 Apr 2026
- Primary completion date
- 31 May 2028
- Lead sponsor
- Janux Therapeutics
- Diseases
- Prostate cancer
- NCT number
- NCT07545811
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 43
- From 15 Apr 2026 to the primary completion date, 31 May 2028
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior solid organ transplant
- Prior treatment with any CAR-T cell therapy, approved or investigational T-cell engager therapy, and prior receipt of radioligand therapy
Other illness
- Clinically significant cardiovascular disease
Who the study is looking for
- Male ≥18 years of age at the time of signing informed consent
- Histologically or cytologically confirmed adenocarcinoma of the prostate
- For Dose Escalation: Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. Participants who have actively refused a taxane containing regimen or are medically unsuitable to receive taxane are eligible.
- Adequate organ function
- For Dose Expansion Part: Have received ≤ 2 anti-androgen therapies in either the HSPC or CRPC setting and no more than 1 prior taxane regimen in the HSPC setting. Participants who have actively refused a taxane regimen or are medically unsuitable to receive taxane are eligible.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of South Carolina - Hollings Cancer Center Coordinator of this site? Confirm its status | Charleston | United States | Recruiting |
| SCRI at Mary Crowley Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
| Prisma Health Cancer Institute Coordinator of this site? Confirm its status | Greenville | United States | Recruiting |
| UC San Diego Moores Cancer Center Coordinator of this site? Confirm its status | La Jolla | United States | Recruiting |
| SCRI Oncology Partners Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.